[go: up one dir, main page]

WO2024118998A3 - Anticorps anti-sars-cov-2 modifiés et leurs méthodes d'utilisation - Google Patents

Anticorps anti-sars-cov-2 modifiés et leurs méthodes d'utilisation Download PDF

Info

Publication number
WO2024118998A3
WO2024118998A3 PCT/US2023/081959 US2023081959W WO2024118998A3 WO 2024118998 A3 WO2024118998 A3 WO 2024118998A3 US 2023081959 W US2023081959 W US 2023081959W WO 2024118998 A3 WO2024118998 A3 WO 2024118998A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
clade
antigen
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/081959
Other languages
English (en)
Other versions
WO2024118998A2 (fr
Inventor
Elisabetta CAMERONI
Davide Corti
Chiara D'AVINO
Susannah Karen DAVIS
Anna Lowegard
Martin Anibal Orecchia
Dora PINTO
Matteo Samuele PIZZUTO
Christopher James Plummer
Martin James SCOTT
Gyorgy Snell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Glaxo Wellcome Uk Ltd
Vir Biotechnology Inc
Original Assignee
Humabs Biomed SA
Glaxo Wellcome Uk Ltd
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA, Glaxo Wellcome Uk Ltd, Vir Biotechnology Inc filed Critical Humabs Biomed SA
Publication of WO2024118998A2 publication Critical patent/WO2024118998A2/fr
Publication of WO2024118998A3 publication Critical patent/WO2024118998A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente divulgation concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci qui peuvent se lier à un antigène du SARS-CoV-2 et, dans certains modes de réalisation, peuvent neutraliser une infection par le SARS-CoV-2. Dans certains modes de réalisation, les anticorps présentement décrits peuvent se lier à des protéines S de multiples sarbécovirus et/ou neutraliser une infection par de multiples sarbécovirus. Dans certains modes de réalisation, un sarbecovirus est issu de la clade 1a, de la clade 1b, de la clade 2 ou de la clade 3. Dans certains modes de réalisation, un sarbecovirus comprend un SARS-CoV-2, un variant G504D du SARS-CoV-2, un variant delta du SARS-CoV, un SARS-CoV, ou toute combinaison de ceux-ci. L'invention concerne également des polynucléotides qui codent pour un anticorps ou un fragment de liaison à l'antigène, des vecteurs et des cellules hôtes qui comprennent un polynucléotide, des compositions pharmaceutiques, ainsi que des méthodes d'utilisation des anticorps, des fragments de liaison à l'antigène, des polynucléotides, des vecteurs, des cellules hôtes et des compositions présentement décrits pour traiter ou diagnostiquer une infection à sarbécovirus, telle qu'une infection par le SARS-CoV-2.
PCT/US2023/081959 2022-12-01 2023-11-30 Anticorps anti-sars-cov-2 modifiés et leurs méthodes d'utilisation Ceased WO2024118998A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263385748P 2022-12-01 2022-12-01
US63/385,748 2022-12-01

Publications (2)

Publication Number Publication Date
WO2024118998A2 WO2024118998A2 (fr) 2024-06-06
WO2024118998A3 true WO2024118998A3 (fr) 2024-07-11

Family

ID=89508964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/081959 Ceased WO2024118998A2 (fr) 2022-12-01 2023-11-30 Anticorps anti-sars-cov-2 modifiés et leurs méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2024118998A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021211775A1 (fr) * 2020-04-14 2021-10-21 Vir Biotechnology, Inc. Anticorps dirigés contre le sras-cov-2 et leurs procédés d'utilisation
WO2021247925A1 (fr) * 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Immunothérapie guidée par une structure dirigée contre le sars-cov-2
WO2022204202A1 (fr) * 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Anticorps qui se lient à de multiples sarbecovirus

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1597280B2 (fr) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Production d'anticorps monoclonaux par transformation de lymphocytes b par le virus d'epstein barr
DE602004030700D1 (de) 2003-09-24 2011-02-03 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin-like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008042814A2 (fr) 2006-09-29 2008-04-10 California Institute Of Technology Récepteurs mart-1 des lymphocytes t
NZ720353A (en) 2013-12-30 2019-12-20 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
JP6587696B2 (ja) 2015-05-13 2019-10-09 ズムトール バイオロジクス、インコーポレイテッド アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
WO2019024979A1 (fr) 2017-07-31 2019-02-07 Institute For Research In Biomedicine Anticorps à domaines fonctionnels dans la région de coude
MY202919A (en) 2017-09-22 2024-05-29 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021211775A1 (fr) * 2020-04-14 2021-10-21 Vir Biotechnology, Inc. Anticorps dirigés contre le sras-cov-2 et leurs procédés d'utilisation
WO2021247925A1 (fr) * 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Immunothérapie guidée par une structure dirigée contre le sars-cov-2
WO2022204202A1 (fr) * 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Anticorps qui se lient à de multiples sarbecovirus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MATHIEU DONDELINGER ET AL: "Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition", FRONTIERS IN IMMUNOLOGY, vol. 9, 16 October 2018 (2018-10-16), pages 1 - 15, XP055572450, DOI: 10.3389/fimmu.2018.02278 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 79, no. 6, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP002683593, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *
TORTORICI M. ALEJANDRA ET AL: "Broad sarbecovirus neutralization by a human monoclonal antibody", NATURE, vol. 597, no. 7874, 2 September 2021 (2021-09-02), pages 103 - 108, XP055845075, Retrieved from the Internet <URL:https://www.nature.com/articles/s41586-021-03817-4.pdf> DOI: 10.1038/s41586-021-03817-4 *
WINKLER K ET AL: "Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 165, no. 8, 15 October 2000 (2000-10-15), pages 4505 - 4514, XP002579393, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2024118998A2 (fr) 2024-06-06

Similar Documents

Publication Publication Date Title
EP4245373A3 (fr) Anticorps contre le sars-cov-2
PH12022500020A1 (en) Antibodies against sars-cov-2
BR112022015374A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
BR112022020706A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
WO2019165122A8 (fr) Anticorps neutralisants dirigés contre la protéine d&#39;enveloppe (env) du vih-1 et leur utilisation
MX2022013894A (es) Anticuerpos neutralizantes que se unen a la proteina s del sars-cov-2.
WO2022067269A3 (fr) Anticorps contre le sars-cov-2
WO2022032003A3 (fr) Anticorps anti-claudine 18.2 et leurs utilisations
WO2024191972A3 (fr) Anticorps anti-lipocaline-2 et leurs utilisations
WO2023205239A3 (fr) Agent thérapeutique à base d&#39;adn codant pour un anticorps ou un fragment de liaison à un antigène
WO2020057742A1 (fr) Vaccin et anticorps contre la toxine de clostidioides difficile
WO2024118998A3 (fr) Anticorps anti-sars-cov-2 modifiés et leurs méthodes d&#39;utilisation
WO2022159839A8 (fr) Anticorps monoclonaux contre les coronavirus et leurs utilisations
WO2023122659A3 (fr) Complexes polypeptidiques de liaison à l&#39;antigène activés de manière conditionnelle et leurs procédés d&#39;utilisation
WO2023060137A3 (fr) Procédés et compositions comprenant des polypeptides de liaison b7-h3
AU2024240129A1 (en) Anti-phosphocholine antibodies and methods of use thereof
ZA202404271B (en) Bispecific cd16a binders
ZA202404272B (en) Bispecific cd16a binders
WO2024031009A3 (fr) Anticorps anti-cd24 et leurs utilisations
WO2024007013A3 (fr) Polypeptides de liaison à l&#39;antigène anti-sars-cov-2, complexes polypeptidiques et leurs procédés d&#39;utilisation
MX2024006969A (es) Anticuerpos dlk1 y metodos de tratamiento del cancer.
WO2023122647A3 (fr) Procédés de détection ou de traitement d&#39;infections grippales
WO2024007012A3 (fr) Polypeptides de liaison à l&#39;antigène anti-sars-cov-2, complexes polypeptidiques et leurs procédés d&#39;utilisation
AU2024255423A1 (en) Antibodies that bind to multiple sarbecoviruses

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23837479

Country of ref document: EP

Kind code of ref document: A2